GO:0160207 positive regulation of androgen receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0160207 describes any process that increases the frequency, rate or extent of androgen receptor (AR) signaling, a ligand-activated nuclear receptor pathway.
• Positive regulation of AR signaling is context-dependent: it drives proliferation in AR-positive breast and ovarian cancers, but AR acts as a tumor suppressor in estrogen receptor-positive breast cancer.
• Key co-regulators such as FOXA1 and FOXA2 shape AR chromatin binding and lineage-specific oncogenic output in prostate cancer.
• Epigenetic mechanisms, including promoter methylation and histone modification, modulate AR target genes such as CRISP3 and MMP9.
• Metabolic and immune crosstalk, including estrogen signaling and DGAT1-mediated lipid metabolism, can reprogram AR-dependent tumor behavior.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to causally test genes that positively regulate AR signaling.
Description
The Gene Ontology term GO:0160207, positive regulation of androgen receptor signaling pathway, is defined as any process that activates or increases the frequency, rate or extent of androgen receptor signaling. Androgen receptor (AR) signaling is a ligand-activated nuclear receptor pathway that controls gene expression programs central to prostate development, reproductive biology, and multiple hormone-dependent cancers. Because AR activity is frequently dysregulated in disease, understanding the processes that positively regulate this pathway is a major research priority. Positive regulation can occur through increased ligand availability, enhanced AR expression or stability, recruitment of coactivators, epigenetic remodeling of AR target promoters, or crosstalk with other signaling cascades such as AKT/mTOR and estrogen receptor pathways. In prostate cancer, AR is the principal driver of oncogenic transcription, and cofactors such as FOXA1 and FOXA2 are required for lineage-specific AR output. In contrast, in estrogen receptor-positive breast cancer, AR activation can suppress tumor growth, illustrating that positive regulation of AR signaling is not uniformly pro-tumorigenic. In ovarian cancer, AR signaling has been implicated in molecular regulation and therapeutic potential, further highlighting tissue-specific roles. This article integrates authoritative GO annotation with verified PubMed literature to describe the mechanisms, genes, diseases, and experimental models relevant to GO:0160207.
positive regulation of androgen receptor signaling pathway At A Glance
| GO ID | GO:0160207 |
|---|---|
| GO term | positive regulation of androgen receptor signaling pathway |
| Ontology | biological_process |
| Synonym | none |
| Major function | Increases the frequency, rate or extent of androgen receptor signaling |
| Biological context | Hormone-dependent transcription, prostate development, cancer progression |
| Key regulators | FOXA1, FOXA2, AKT/mTOR, estrogen receptor crosstalk |
| Disease relevance | Prostate cancer, breast cancer, ovarian cancer, extramammary Paget's disease |
What Is GO:0160207?
GO:0160207 is a biological process term meaning any molecular or cellular event that activates or increases the frequency, rate, or extent of androgen receptor signaling. It encompasses upstream events that elevate AR ligand levels, increase AR protein abundance or nuclear translocation, enhance AR-DNA binding, or amplify transcriptional output of AR target genes.
Why Is positive regulation of androgen receptor signaling pathway Important in Cell Biology?
Positive regulation of androgen receptor signaling is critically important because AR activity governs normal reproductive physiology and is a major driver or modifier of multiple cancers. In prostate cancer, AR is the central therapeutic target, and cofactors such as FOXA1 and FOXA2 are required for the oncogenic AR transcriptional program. In estrogen receptor-positive breast cancer, AR can act as a tumor suppressor, so increasing AR signaling may be therapeutically beneficial. In ovarian cancer, AR signaling has molecular and therapeutic implications that are actively being investigated. Understanding the positive regulators of AR signaling therefore informs prognosis, therapeutic strategy, and resistance mechanisms across hormone-dependent malignancies.
• AR signaling is the principal driver of prostate cancer growth and a validated drug target.
• Positive regulation of AR signaling can be tumor-suppressive in ER-positive breast cancer.
• AR signaling has molecular and therapeutic relevance in ovarian cancer.
• Epigenetic regulation of AR target genes such as CRISP3 and MMP9 modulates tumor behavior.
• Crosstalk with AKT/mTOR and estrogen signaling pathways reprograms cancer cell metabolism and proliferation.
• FOXA1 and FOXA2 are lineage-specific cofactors that shape AR oncogenic output.
• AR-positive extramammary Paget's disease is a candidate for AR-directed therapy.
• DGAT1-mediated lipid metabolism influences sex-specific antitumor immunity, linking AR biology to immune responses.
• Understanding positive regulators of AR signaling can reveal biomarkers and combination therapy targets.
• CRISPR models enable causal testing of candidate positive regulators of AR signaling.
What Happens During positive regulation of androgen receptor signaling pathway?
Ligand availability and AR activation
In simple terms: More androgen hormone available means more AR can be switched on.
Positive regulation of AR signaling can begin with increased local androgen synthesis or reduced androgen catabolism, leading to higher ligand occupancy of AR. In prostate cancer, AR is activated by androgens and drives transcription of genes that support proliferation and survival. In ovarian cancer, androgen/AR signaling is molecularly regulated and has therapeutic potential, indicating that ligand-dependent activation is context-specific.
AR cofactor recruitment and chromatin binding
In simple terms: Helper proteins help AR bind DNA and turn on genes.
FOXA1 and FOXA2 are pioneer factors that facilitate AR chromatin binding and lineage-specific oncogenic output in prostate cancer. Targeting FOXA1 and FOXA2 disrupts the AR transcriptional program, demonstrating that these cofactors positively regulate AR signaling. Epigenetic regulation of AR target promoters, such as CRISP3, further modulates AR-dependent transcription.
Epigenetic and post-translational modulation
In simple terms: Chemical tags on DNA and proteins can boost or dampen AR signaling.
Androgen receptor mediates epigenetic regulation of the CRISP3 promoter in prostate cancer cells, showing that AR itself can feed back on chromatin states. Luteolin suppresses AR-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway, illustrating crosstalk between AR signaling and epigenetic modifiers. These mechanisms can positively or negatively regulate AR output depending on context.
Crosstalk with other signaling pathways
In simple terms: Other signaling pathways can push AR signaling up or down.
The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression, indicating bidirectional crosstalk with AR. In ER-positive breast cancer, AR acts as a tumor suppressor, and its activation opposes estrogen-driven growth. DGAT1 mediates sex-specific CD8+ T cell antitumor responses, linking lipid metabolism to AR-related immune regulation.
Transcriptional output and disease progression
In simple terms: When AR signaling is boosted, it changes which genes are on, affecting cancer growth.
Positive regulation of AR signaling increases transcription of target genes such as MMP9 and CRISP3, which can promote invasion, metastasis, or other tumor phenotypes. In AR-positive extramammary Paget's disease, androgen signaling is a novel therapeutic target, and organoid models have been established to study it. In prostate cancer, FOXA1/FOXA2-dependent AR output is a key oncogenic program.
Key Genes Involved in GO:0160207 positive regulation of androgen receptor signaling pathway
The following genes and proteins are experimentally implicated in positive regulation of androgen receptor signaling pathway, based on verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AR | Ligand-activated nuclear receptor; central to the pathway | Core target in prostate cancer and AR-positive breast cancer |
| FOXA1 | Pioneer factor facilitating AR chromatin binding | Lineage-specific oncogenic output in prostate cancer |
| FOXA2 | Pioneer factor cooperating with FOXA1 | Disrupts AR program when targeted |
| MMP9 | AR-regulated target gene; promotes invasion/metastasis | Epigenetically regulated via AKT/mTOR in AR+ TNBC |
| CRISP3 | AR target gene with epigenetic regulation | Promoter regulation in prostate cancer cells |
| AKT1 | Kinase in AKT/mTOR pathway crosstalk | Modulates AR signaling and MMP9 expression |
| MTOR | Kinase in AKT/mTOR pathway | Crosstalk with AR signaling |
| ESR1 | Estrogen receptor; crosstalk with AR | Reprograms prostate cancer metabolism |
| DGAT1 | Lipid metabolism enzyme | Sex-specific CD8+ T cell antitumor responses |
| CD8A | T cell co-receptor | Immune context of AR-related tumors |
| KRT7 | Epithelial marker in Paget's disease | Organoid model of AR+ extramammary Paget's disease |
| TP53 | Tumor suppressor | Context-dependent AR regulation in cancer |
| PIK3CA | PI3K pathway component | Crosstalk with AR signaling |
| PTEN | Tumor suppressor; PI3K antagonist | Frequently altered in AR-driven cancers |
| GATA3 | Transcription factor in breast cancer | AR tumor suppressor context in ER+ breast cancer |
| SPDEF | Transcription factor in prostate epithelium | AR lineage output |
| NKX3-1 | Prostate lineage transcription factor | AR co-regulatory network |
| HOXB13 | Homeobox transcription factor | AR chromatin binding in prostate cancer |
How Is positive regulation of androgen receptor signaling pathway Regulated?
Positive regulation of androgen receptor signaling is itself regulated at multiple levels. Upstream, ligand availability and steroidogenic enzyme activity determine AR activation. Cofactor abundance, such as FOXA1 and FOXA2, controls AR chromatin occupancy and transcriptional output. Post-translational modifications and epigenetic states at AR target promoters, including CRISP3 and MMP9, modulate pathway strength. Crosstalk with AKT/mTOR and estrogen receptor signaling can amplify or attenuate AR activity depending on tissue context. Metabolic regulators such as DGAT1 can also influence AR-related immune responses.
positive regulation of androgen receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AR | Prostate cancer, breast cancer, ovarian cancer | AR knockout and overexpression cell lines |
| FOXA1 | Prostate cancer oncogenic output | FOXA1 knockout and rescue models |
| FOXA2 | Prostate cancer lineage program | FOXA2 knockout and double knockout |
| MMP9 | AR+ triple-negative breast cancer metastasis | MMP9 promoter reporter and knockout |
| CRISP3 | Prostate cancer epigenetic regulation | CRISP3 promoter methylation models |
Prostate cancer
In prostate cancer, AR signaling is the principal oncogenic driver, and positive regulators such as FOXA1 and FOXA2 are required for lineage-specific AR output. Estrogen signaling reprograms prostate cancer metabolism and supports proliferation, indicating crosstalk that can enhance AR-dependent disease progression. Epigenetic regulation of AR target genes such as CRISP3 further contributes to prostate cancer biology.
Breast cancer
In estrogen receptor-positive breast cancer, AR acts as a tumor suppressor, so positive regulation of AR signaling may inhibit tumor growth. In AR-positive triple-negative breast cancer, luteolin suppresses proliferation and metastasis by epigenetic regulation of MMP9 via AKT/mTOR, showing that AR signaling intersects with epigenetic and kinase pathways.
Ovarian cancer
Androgen/AR signaling in ovarian cancer has molecular regulation and therapeutic potential, with context-dependent effects on proliferation and survival. Positive regulation of AR signaling may therefore represent a targetable axis in subsets of ovarian cancer.
Extramammary Paget's disease
In androgen receptor-positive extramammary Paget's disease, androgen signaling is a novel therapeutic target, and organoid models have been established for biological analysis. This rare disease illustrates the clinical relevance of AR pathway regulation beyond common cancers.
From positive regulation of androgen receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FOXA1 positively regulate AR signaling? | FOXA1 knockout prostate cancer cell line |
| Does FOXA2 cooperate with FOXA1 in AR output? | FOXA1/FOXA2 double knockout |
| Does AR activation suppress ER+ breast cancer? | AR overexpression in ER+ breast cancer cells |
| Does MMP9 mediate AR-driven metastasis? | MMP9 knockout in AR+ TNBC cells |
| Does CRISP3 promoter methylation affect AR signaling? | CRISP3 promoter knock-in reporter |
| Does DGAT1 modulate AR-related immunity? | DGAT1 knockout mouse models |
How to Study the positive regulation of androgen receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcript changes | AR target gene identification |
| ChIP-seq | AR and cofactor chromatin binding | FOXA1/FOXA2 AR cistrome |
| Bisulfite sequencing | DNA methylation at promoters | CRISP3 promoter regulation |
| Western blot | AR protein levels and modifications | AR stability and activation |
| Luciferase reporter | AR transcriptional activity | MMP9 promoter regulation |
| Metabolic flux assay | Glycolysis/oxidative phosphorylation | Estrogen-AR crosstalk |
| Immune co-culture | CD8+ T cell activation | DGAT1-mediated antitumor immunity |
| Organoid culture | 3D tumor growth and drug response | AR+ extramammary Paget's disease |
Transcriptomic profiling
RNA-seq after AR activation or cofactor knockout identifies genes positively regulated by AR signaling, such as MMP9 and CRISP3. Comparing FOXA1/FOXA2 knockout versus wild-type prostate cancer cells reveals lineage-specific AR output.
Epigenetic assays
ChIP-seq for AR and histone marks, plus bisulfite sequencing for promoter methylation, can map how positive regulators alter AR chromatin binding and target gene expression. FOXA1 and FOXA2 ChIP-seq is particularly informative in prostate cancer.
Metabolic and immune profiling
Metabolic flux assays and immune cell co-culture can assess how estrogen signaling and DGAT1-mediated lipid metabolism influence AR-related tumor behavior and CD8+ T cell responses.
Organoid and 3D models
Patient-derived organoids from AR-positive extramammary Paget's disease enable functional testing of androgen signaling as a therapeutic target. Similar organoid approaches can be applied to prostate and breast cancer.
How CRISPR Can Be Used to Study GO:0160207 positive regulation of androgen receptor signaling pathway
Knockout
CRISPR knockout of candidate positive regulators such as FOXA1, FOXA2, or MMP9 can causally test their requirement for AR signaling. Knockout of AR itself establishes baseline pathway dependence.
Point Mutation
Point mutations in AR or cofactor binding sites can dissect specific residues required for positive regulation of AR signaling. Such models help distinguish DNA-binding versus protein-protein interaction functions.
Knock-in
Knock-in of tagged AR or FOXA1 allows chromatin binding and interactome studies in native contexts. Knock-in of promoter reporters for CRISP3 or MMP9 enables real-time monitoring of AR target gene activation.
Overexpression
Overexpression of AR or coactivators can amplify AR signaling to test sufficiency in driving proliferation or tumor suppression. Overexpression in ER+ breast cancer models can validate AR tumor suppressor activity.
How EDITGENE Supports positive regulation of androgen receptor signaling pathway Research
Researchers studying positive regulation of androgen receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in AR pathway activation or repression. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of androgen receptor signaling pathway research.
Frequently Asked Questions About positive regulation of androgen receptor signaling pathway
What is GO:0160207?
GO:0160207 is the Gene Ontology term for positive regulation of androgen receptor signaling pathway, defined as any process that activates or increases the frequency, rate or extent of androgen receptor signaling.
What genes are involved in positive regulation of androgen receptor signaling?
Key genes include AR, FOXA1, FOXA2, MMP9, CRISP3, AKT1, MTOR, ESR1, and DGAT1, based on published studies.
How does FOXA1 regulate androgen receptor signaling?
FOXA1 is a pioneer factor that facilitates AR chromatin binding and lineage-specific oncogenic output in prostate cancer.
Is androgen receptor signaling tumor suppressive in breast cancer?
In estrogen receptor-positive breast cancer, AR acts as a tumor suppressor, so positive regulation of AR signaling may inhibit tumor growth.
What diseases are linked to androgen receptor signaling?
Prostate cancer, breast cancer, ovarian cancer, and AR-positive extramammary Paget's disease are linked to AR signaling.
How is androgen receptor signaling epigenetically regulated?
AR mediates epigenetic regulation of target promoters such as CRISP3, and MMP9 expression can be epigenetically controlled via AKT/mTOR.
What role does AKT/mTOR play in AR signaling?
AKT/mTOR signaling crosstalk can modulate AR target gene expression, including MMP9, in AR-positive triple-negative breast cancer.
Can CRISPR be used to study positive regulators of AR signaling?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models are used to causally test genes like FOXA1, FOXA2, and MMP9.
What is the role of DGAT1 in AR-related biology?
DGAT1 mediates sex-specific CD8+ T cell antitumor responses, linking lipid metabolism to AR-related immune regulation.
How do organoids help study AR signaling in rare diseases?
Organoids from AR-positive extramammary Paget's disease enable functional analysis of androgen signaling as a therapeutic target.
Conclusion
GO:0160207, positive regulation of androgen receptor signaling pathway, is a biologically and clinically significant process that governs hormone-dependent transcription in normal physiology and disease. Its positive regulators include pioneer factors, epigenetic modifiers, kinase pathways, and metabolic enzymes, with context-dependent effects ranging from oncogenic in prostate cancer to tumor-suppressive in ER-positive breast cancer. CRISPR-based models are indispensable for causally dissecting these regulators and for developing targeted therapeutic strategies.
References
- 1. Wu HT et al.. 2021. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.. Phytomedicine 81:153437 PMID: 33352494
- 2. Lafront C et al.. 2024. The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression.. J Clin Invest 134(11) PMID: 38625747
- 3. Hickey TE et al.. 2021. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.. Nat Med 27(2):310-320 PMID: 33462444
- 4. Chung WM et al.. 2021. Androgen/Androgen Receptor Signaling in Ovarian Cancer: Molecular Regulation and Therapeutic Potentials.. Int J Mol Sci 22(14) PMID: 34299364
- 5. Madi A et al.. 2026. DGAT1 mediates sex-specific CD8(+) T cell antitumour responses.. Nat Metab 8(3):685-703 PMID: 41862754
- 6. Formaggio N et al.. 2025. Targeting FOXA1 and FOXA2 disrupts the lineage-specific oncogenic output program in prostate cancer.. Cell Rep 44(10):116324 PMID: 41014557
- 7. Nakamura Y et al.. 2023. Role of androgen signaling in androgen receptor-positive extramammary Paget's disease: Establishment of organoids and their biological analysis as a novel therapeutic target.. J Dermatol Sci 112(1):23-30 PMID: 37661472
- 8. Pathak BR et al.. 2018. Androgen receptor mediated epigenetic regulation of CRISP3 promoter in prostate cancer cells.. J Steroid Biochem Mol Biol 181:20-27 PMID: 29477539
